Amantadine for fatigue in multiple sclerosis - Wikidata - awgldk - TriplyDB

Amantadine for fatigue in multiple sclerosis

Amantadine for fatigue in multiple sclerosis

http://www.wikidata.org/entity/Q24246259

about

Interventions for fatigue in peripheral neuropathy Pharmacological treatments for fatigue associated with palliative care Carnitine for fatigue in multiple sclerosis Interventions for fatigue and weight loss in adults with advanced progressive illness Pharmacological treatments for fatigue associated with palliative care Carnitine for fatigue in multiple sclerosis Interventions for fatigue in peripheral neuropathy Pharmacological treatments for fatigue associated with palliative care: executive summary of a Cochrane Collaboration systematic review Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders.Multi-centre parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based cognitive behavioural approach to managing fatigue in people with multiple sclerosis Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation Fatigue and physical disability in patients with multiple sclerosis: a structural equation modeling approach Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.Fatigue in patients with multiple sclerosis: is it related to pro- and anti-inflammatory cytokines?Treatment of fatigue in multiple sclerosis patients: a neurocognitive approach.Neurophysiological Correlates of Central Fatigue in Healthy Subjects and Multiple Sclerosis Patients before and after Treatment with Amantadine.Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis.Development and Feasibility of an Evidence-Based Patient Education Program for Managing Fatigue in Multiple Sclerosis: The "Fatigue Management in MS" Program (FatiMa).Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.Effect of a Single Bout of Intermittent versus Continuous Walking on Perceptions of Fatigue in People with Multiple Sclerosis.WITHDRAWN: Interventions for fatigue and weight loss in adults with advanced progressive illness.Health benefits of methylxanthines in neurodegenerative diseases.Managing Disability in Progressive Multiple Sclerosis.The Role of Dopamine in Inflammation-Associated Depression: Mechanisms and Therapeutic Implications.Inflammation Effects on Motivation and Motor Activity: Role of Dopamine.Amantadine: multiple sclerosis-related fatigue.Imaging the role of inflammation in mood and anxiety-related disorders.Explaining fatigue in multiple sclerosis: cross-validation of a biopsychosocial model.Learning to live well with chronic fatigue: the personal perspective.Dietary approaches to treat MS-related fatigue: comparing the modified Paleolithic (Wahls Elimination) and low saturated fat (Swank) diets on perceived fatigue in persons with relapsing-remitting multiple sclerosis: study protocol for a randomized c Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study

P2860

Q24187233-9CF69B87-1B2E-4EBD-A07F-59A23637ED3E Q24187756-C7356862-0B72-4CB7-8049-68AC0DEE084A Q24197748-DCEA6B0E-0624-4B58-9075-431D951D9A82 Q24203914-E934845A-63FC-4EC2-B6E5-FF396D6E0935 Q24236457-1A178A42-DF28-46BF-B423-B36F62C6922C Q24240036-B0C0AC83-F739-4D3A-BC50-0672F4962A7D Q24240807-79E6540E-E607-43D4-AF2B-AB530D20402B Q26749413-F48A2258-EA85-4E00-B212-70269213E7D0 Q27001628-E03728D2-F7D1-427E-ADEB-383579463760 Q28073849-83B94F16-03D4-4F02-8065-E156A30D41C0 Q30917626-A1E5E85F-0EB2-4211-9375-D82C3718AF42 Q33606260-0FA23C52-307D-480C-84E2-60F81AE3FE63 Q33735739-1700D5F3-D6DA-425C-973A-0693DC7ECAD0 Q33887434-172C99A4-F0FF-4E78-95E9-9969DA57763B Q34098558-43D0631F-59AB-4C8C-9561-6CC431358C9D Q35018491-7054A9AF-81DD-4172-964B-ACF808E45CDB Q35036908-EDEC9616-D10A-4A99-A98B-2FFB130EDDF5 Q35390868-BAD069DF-F64D-4B98-8327-F1EE6D67F138 Q35864382-1A6CEEA6-05CF-4867-A8E7-7718BC51CBEB Q36628420-86FD5E60-70F5-4E22-A8FB-9B923ACEB5BE Q36889694-2DF4807A-4AF0-430C-AE2A-DE428CE4E1CA Q36951364-52517559-3F79-4DE3-9A1A-3C94A4359E81 Q37089253-1E5941E9-151A-49C7-8984-139AA240088F Q37442256-2F59CA66-4F98-41EA-8F46-6D0559A27F08 Q38733702-3E275838-59FF-4CAB-8740-37A443A2E30E Q38772021-F2F6B5AD-17A9-456D-AD85-806A43718386 Q38811069-70286148-0D13-4189-AF47-E78332668CD8 Q38844378-C26C1070-33A9-48FC-B805-C8CED3EDAC30 Q38915253-A445E7FF-3BAD-4B51-860E-83C2F237B748 Q42107853-CD1A7F51-3034-4814-8170-88F149EDF1BD Q47305318-7B756A49-D1EF-4544-A3DD-F28DF8E8BA74 Q47426011-A9394345-308F-410C-B143-8E460C890CE4 Q51862725-46E77EAE-F12E-4981-B06D-0AF5171F416C Q55253433-A4DF3E54-2CAF-4E8F-B212-47FF76371959 Q56543777-0BDFA5EA-33FE-4FCF-A74A-9E3AB7BC96D5

P2860

Amantadine for fatigue in multiple sclerosis

http://www.wikidata.org/entity/Q24246259

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Amantadine for fatigue in multiple sclerosis

@ast

Amantadine for fatigue in multiple sclerosis

@en

Amantadine for fatigue in multiple sclerosis

@en-gb

Amantadine for fatigue in multiple sclerosis

@nl

type

label

Amantadine for fatigue in multiple sclerosis

@ast

Amantadine for fatigue in multiple sclerosis

@en

Amantadine for fatigue in multiple sclerosis

@en-gb

Amantadine for fatigue in multiple sclerosis

@nl

prefLabel

Amantadine for fatigue in multiple sclerosis

@ast

Amantadine for fatigue in multiple sclerosis

@en

Amantadine for fatigue in multiple sclerosis

@en-gb

Amantadine for fatigue in multiple sclerosis

@nl

P1433

Q24246259-60F789BE-AD9B-47F0-AF67-18827CE86E78

P1476

Q24246259-0E7422D9-6C52-4A04-83ED-90D120597412

P2093

Q24246259-9C4AC7A1-C4CE-4B00-BBB7-E8ED4DB3D768

Q24246259-C7EF0238-86A2-45A9-B206-474ABFB4AA9B

Q24246259-EA2A6066-F4F8-406E-B926-11532015261D

Q24246259-FC1DFA69-B012-4B3B-BB31-50C18BAB0471

P2860

Q24246259-03BA0E50-4DF0-41A4-B74E-080F8DE9DC95

Q24246259-068BF992-D136-439B-B1C0-FD48BF8DE3D2

Q24246259-0BA14EBD-A22A-4B91-B63A-4FAE74D7B78E

Q24246259-0EE55B7F-BBA1-4573-991C-3772BD09DAD5

Q24246259-12B9381F-D2C3-49F0-B0F9-C04ABE5436C4

Q24246259-14ADB503-67CB-4FAD-91CA-044DBAB8B210

Q24246259-1945454B-7D1D-4F22-B0EC-BCD148986B20

Q24246259-1BA6BFFA-772B-4543-BBA0-F5D4025D1E79

Q24246259-22F8A967-2A39-459B-8382-6EED3E2CE27B

Q24246259-2355E215-3C78-4AE4-99DB-CD1755DF5DB0

P304

Q24246259-8DFC7A15-A599-4298-88D0-692409DDE0D9

P31

Q24246259-ED268022-4183-49BC-B0D8-FE83E27292A8

P356

Q24246259-C854DCBA-09D4-4EBF-B5AC-EBA0900966DD

P407

Q24246259-F4FF98AE-9A9E-49EB-9CC5-F7F9272413B7

P433

Q24246259-73323ED9-C849-43D2-B8F4-8E8554CDBD8C

P50

Q24246259-07F2543C-5732-4369-8C36-9B8C3579E034

Q24246259-C41C25A5-98E7-4439-90C6-70AE3B335A81

P577

Q24246259-96D272CA-74E0-4CC8-9F8E-02198A54001A

P698

Q24246259-77BAB4D9-7D43-48AB-BD36-CBA5E92B0491

P921

Q24246259-265CA100-DA65-4297-8E91-55EFCA97560F

P932

Q24246259-E3B5CF98-8B1F-43F5-8BF7-74D4E28CC3A1

P356

14651858.CD002818.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Amantadine for fatigue in multiple sclerosis

@en

P2093

A Solari

http://www.w3.org/2001/XMLSchema#string

C Taus

http://www.w3.org/2001/XMLSchema#string

G Giuliani

http://www.w3.org/2001/XMLSchema#string

P Branãs

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

Amantadine and rimantadine for influenza A in adults

Amantadine for dyskinesia in Parkinson's disease

Amantadine in Parkinson's disease

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

An Inventory for Measuring Depression

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Antivirals for influenza in healthy adults: systematic review.

Amantadine treatment of fatigue associated with multiple sclerosis.

P304

CD002818

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/14651858.CD002818.PUB2

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P50

Roberto D'Amico

P577

2007-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17253480

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

6991937

http://www.w3.org/2001/XMLSchema#string